Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Hypochlorous acid is safe enough to spray in your eyes yet more effective than bleach. Why isn’t it everywhere?

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Variations in inflammation may contribute to vaso-occlusive events (VOEs) during the menstrual cycles of women with SCD, per a study.

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

VIENNA – Irish researchers presented data Saturday at the European Society of Clinical Microbiology and Infectious Diseases global congress validating interleukin-6 as an early detection biomarker for ...

VIENNA – Irish researchers presented data Saturday at the European Society of Clinical Microbiology and Infectious Diseases global congress validating interleukin-6 as an early detection biomarker for ...

Corinthia Black studies the anatomical features of fishes and spiders to understand how life on Earth takes shape ...

Deciphering the gut biome's, including helminths', influence on human trained immunity will unlock novel immunotherapies harnessing the immune reprogramming potential of their secreted factors and ...